Category: Europe

March 6, 2017 Off

Novartis’s Cosentyx shows good results in psoriasis retreatment

By Dino Mustafić

Novartis has reported new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause. Also showed no anti-secukinumab antibodies were observed during retreatment.

March 3, 2017 Off

Sanofi, AstraZeneca making Respiratory Syncytial Virus vaccine

By Dino Mustafić

Sanofi’s vaccines global business unit Sanofi Pasteur has signed a deal with AstraZeneca’s biologics bramch MedImmune, to make and sell a monoclonal antibody-called MEDI8897-for the prevention of the most common reason for lower respiratory tract infections in newborns and infants, Respiratory Syncytial Virus (RSV).

March 2, 2017 Off

NICE’s approval of Merck’s Erbitux combination gives more choice for mCRC patients in England

By Dino Mustafić

English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.

March 2, 2017 Off

PureTech Health gets new strategist to help CEO

By Dino Mustafić

PureTech Health has named Bharatt Chowrira as its President and Chief of Business and Strategyto work with the Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline, the company said in its annoucement on Thursday.